Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

The Lancet
Nov 07, 2020 Volume 396 Number 10261 p1463-1534, e73-e82
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
Brian J Ward, et al